Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Eflornithine Plus Sulindac in Preventing Colorectal Cancer in Patients With Benign Colorectal Polyps

This study has been completed.
Chao Family Comprehensive Cancer Center
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Vanessa Wong, University of California, Irvine Identifier:
First received: June 2, 2000
Last updated: January 28, 2013
Last verified: January 2013

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of eflornithine and sulindac may be an effective way to prevent the development of colorectal cancer in patients who have had surgery to remove benign colorectal polyps.

PURPOSE: Randomized, double-blinded, phase II trial to determine the effectiveness of eflornithine plus sulindac compared to a placebo in preventing colorectal cancer in patients who have had surgery to remove benign colorectal polyps.

Condition Intervention Phase
Colorectal Cancer
Drug: eflornithine plus sulindac
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase II Clinical Trial of a Randomized, Double-Blind, Placebo Controlled Clinical Trial of DFMO and Sulindac Against Various Endpoints of Colorectal Pathobiology in a Cohort of Individuals at Increased Risk of Colorectal Carcinoma

Resource links provided by NLM:

Further study details as provided by University of California, Irvine:

Primary Outcome Measures:
  • To measure the efficacy of DFMO plus Sulindac versus placebo in modulating biomarkers of colorectal neoplasia. [ Time Frame: 36 months post-randomization ]

Enrollment: 324
Study Start Date: June 2000
Study Completion Date: December 2011
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DFMO+sulindac Drug: eflornithine plus sulindac
Patients will be randomized to 36 months of treatment with either DFMO+sulindac or placebo.
Experimental: Placebo Drug: eflornithine plus sulindac
Patients will be randomized to 36 months of treatment with either DFMO+sulindac or placebo.

Detailed Description:


  • Compare the efficacy of eflornithine (DFMO) and sulindac vs placebo in modulating a panel of surrogate endpoint biomarkers (SEB) of particular relevance in colorectal neoplasia, including quantitative histopathology, uninduced apoptosis, proliferative (Ki67) and preneoplastic (CEA, sialyl-TN, p53, and bcl-2) features, and polyamine and PGE2 levels in patients with at least one previously resected colorectal adenoma.
  • Determine the relationship between the modulation of SEB in flat mucosa and the development of interval incident colorectal adenomas in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to aspirin use (yes vs no) and participating center.

Patients receive oral placebo daily for the first 4 weeks. Patients who are compliant and take the placebo 5 to 7 days each week are randomized to one of two treatment arms.

  • Arm I: Patients receive oral sulindac and oral eflornithine (DFMO) daily.
  • Arm II: Patients receive oral placebo daily. Treatment continues for 3 years in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: Approximately 240 patients (120 per treatment arm) will be accrued for this study within 18 months.


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • At least 1 prior resected colorectal adenoma within the past 5 years

    • At least 3 mm in size
  • No personal or family history of familial adenomatous polyposis



  • 40 to 80

Performance status:

  • SWOG 0-1

Life expectancy:

  • Not specified


  • Hematocrit at least 35%
  • WBC at least 4,000/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 2.0 mg/dL
  • AST and ALT no greater than 2 times normal


  • Creatinine no greater than 1.5 mg/dL
  • No greater than 1+ protein, 0-3 casts, and 0-5 WBCs and RBCs in urine


  • No requirement for special diet or additives
  • No diet that would preclude taking study medications
  • No gastric or duodenal ulcer within the past year
  • No inflammatory bowel disease


  • No more than 20 dB hearing loss for age at any frequency
  • No prior or concurrent invasive cancer within the past 5 years except nonmelanomatous skin cancer, melanoma in situ, stage I cervical cancer, stage I colon cancer, or stage 0 chronic lymphocytic leukemia
  • No severe metabolic disorder or other acute or chronic diseases
  • No history of or predisposition to abnormal wound healing or repair
  • No allergies to nonsteroidal anti-inflammatories or eflornithine
  • Not pregnant or nursing
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • No concurrent chemotherapy

Endocrine therapy:

  • No concurrent corticosteroids


  • No concurrent radiotherapy


  • See Disease Characteristics


  • No other concurrent nonsteroidal anti-inflammatories or anticoagulants administered on a regular or predictable intermittent basis
  • No concurrent aspirin greater than 81 mg per day or 325 mg twice a week for cardiovascular disease prophylaxis
  • No concurrent calcium supplements greater than 500 mg/day
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00005882

United States, Arizona
Arizona Cancer Center
Tucson, Arizona, United States, 85724-5024
United States, California
Veterans Affairs Medical Center - Loma Linda (Pettis)
Loma Linda, California, United States, 92357
Chao Family Comprehensive Cancer Center
Orange, California, United States, 92868
United States, Colorado
University of Colorado Cancer Center
Denver, Colorado, United States, 80010
Sponsors and Collaborators
University of California, Irvine
Chao Family Comprehensive Cancer Center
National Cancer Institute (NCI)
Study Chair: Frank L. Meyskens, MD, FACP Chao Family Comprehensive Cancer Center
  More Information

Abstract A29: Rectal mucosal polyamine and PGE2 levels and risk of colorectal adenomas in a phase IIb/III trial of combination difluoromethylornithine (DFMO) plus sulindac Patricia A. Thompson, Betsy C. Wertheim, Jason A. Zell, Bonnie LeFleur, Wen-Pin Chen, Christine E. McLaren, Frank L. Meyskens, and Eugene W. Gerner Cancer Prev Res January 7, 2010 3:A29; doi:10.1158/1940-6207.PREV-09-A29

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Vanessa Wong, User Account Contact, University of California, Irvine Identifier: NCT00005882     History of Changes
Other Study ID Numbers: CDR0000067922
1997-96 ( Other Identifier: University of California, Irvine )
Study First Received: June 2, 2000
Last Updated: January 28, 2013

Keywords provided by University of California, Irvine:
colon cancer
rectal cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Trypanocidal Agents
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Ornithine Decarboxylase Inhibitors processed this record on April 26, 2017